Prince Edward Island's chief public health office confirms two new cases of measles
The Island's public health office says the infected individuals had visited a number of places since June 21, potentially exposing other people to the highly infectious virus. As a result, the province has produced a list of locations considered potential exposure sites.
The 10 locations include the Charlottetown Airport on June 25 and West Jet flights the same day from Kamloops, B.C., to Calgary, and from Calgary to Charlottetown.
Other locations on the Island include service stations in Stanley Bridge and Scotchfort, a chapel in Charlottetown and a number of retail outlets in Charlottetown and Morell.
As of June 14, Health Canada was reporting 3,381 cases of measles across Canada since the beginning of the year. Ontario was reporting 2,186 cases and Alberta had 961 cases. The two provinces accounted for 93 cent of all cases.
Story continues below advertisement
2:05
Rising measles cases could lead to more problems down the road
Measles spreads through the air and close contact, such as breathing, coughing or sneezing — and it can cause a serious illness that may require admission to a hospital.
Get weekly health news
Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up
By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy
Symptoms include fever, coughing, runny nose, red eyes and a blotchy, red rash that appears three to seven days after the fever starts.
Vaccination against measles is close to 100 per cent effective in preventing the disease.
Health Canada says measles was eliminated in the country in 1998, but recent outbreaks in Alberta have been the most severe in almost 40 years. Across the country, 46 per cent of infections have been reported among those between the ages of 5 and 17, followed by those between the ages of 18 and 54 at 27 per cent.
Meanwhile, Ontario reported its first death related to a measles outbreak on June 5. Ontario officials confirmed that a premature baby died after being infected in the womb of their unvaccinated mother.
Story continues below advertisement
On Wednesday, British Columbia Premier David Eby said the spread of measles is the predictable outcome of the 'recklessness' of anti-vaccination politicians. He told a Vancouver news conference that the focus for provincial public health authorities must be making sure people who are not protected receive vaccinations.
'I will encourage all British Columbians to ensure that they are vaccinated,' Eby said. 'Measles is no joke. It kills kids. It's a preventable disease, and we don't want that to be the story of the summer for our province.'
This report by The Canadian Press was first published June 27, 2025.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
2 hours ago
- Cision Canada
Public advisory - Risk of anaphylactic reaction associated with glatiramer acetate, used to treat multiple sclerosis Français
, /CNW/ - Summary Product: Glatiramer acetate Issue: Health products – Product safety, new safety information What to do: If you experience anaphylactic reaction symptoms, stop taking glatiramer acetate and seek immediate medical help by calling 9-1-1. Report any health product-related side effects to Health Canada. Do not restart taking glatiramer acetate unless your healthcare provider has identified another clear cause for the anaphylaxis. Affected products Issue Health Canada is warning patients that they may experience anaphylactic reactions after receiving glatiramer acetate, which is used to treat relapsing-remitting multiple sclerosis. These anaphylactic reactions can be fatal and may occur at any point during treatment, from as soon as the first dose to months or even years after starting therapy. Anaphylactic reaction symptoms generally appear within one hour of injection and may include: Sudden shortness of breath, wheezing, or difficulty breathing Swelling of the eyelids, face, lips, mouth, tongue, or throat Uncontrolled shaking Fainting or dizziness Trouble swallowing or speaking Widespread rash, hives Collapse Health Canada confirmed this new safety risk following a review of all available data, including 11 Canadian cases of anaphylactic reactions from Copaxone and three additional cases from other glatiramer acetate products. While there have been no fatal cases reported in Canada, some cases required treatment with epinephrine and other appropriate medical interventions. There have been fatal cases reported internationally. Health Canada has informed healthcare professionals, including neurologists, emergency room physicians and staff, nurses, and pharmacists about this new safety risk. The manufacturer for Copaxone has updated its Canadian product labelling to include this risk, and Health Canada is working with the manufacturers of other glatiramer acetate products — including Glatect and Mylan glatiramer acetate injection — to update their respective labelling. What you should do If you experience anaphylactic reaction symptoms, stop taking glatiramer acetate and seek immediate medical help by calling 9-1-1. Do not restart taking glatiramer acetate if you have experienced anaphylaxis unless your healthcare provider has identified another clear cause for the anaphylaxis. Report any health product-related side effects to Health Canada. What healthcare professionals should do Inform patients and/or caregivers of the signs and symptoms of anaphylactic reactions, which may overlap with those of an immediate post-injection reaction. Instruct patients to seek immediate emergency medical care in the event of an anaphylactic reaction. Instruct patients to discontinue treatment with glatiramer acetate if they have an anaphylactic reaction. Do not restart the medicine unless there is another clear reason the patient experienced an anaphylactic reaction. Également disponible en français
Cision Canada
7 hours ago
- Cision Canada
Health Canada grants marketing authorization for an additional indication of Bayer's NUBEQA® (darolutamide) for the treatment of metastatic castration-sensitive prostate cancer (mCSPC) Français
Today's marketing authorization is based on recent results from the Phase III ARANOTE trial and broadens the indication profile of darolutamide in metastatic hormone-sensitive prostate cancer (mCSPC), enabling its use in combination with ADT, with or without chemotherapy (docetaxel) MISSISSAUGA, ON, Aug. 21, 2025 /CNW/ - Bayer Inc. is pleased to announce that Health Canada has granted marketing authorization for its oral androgen receptor inhibitor (ARi) NUBEQA ® (darolutamide) 1 for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC). This marketing authorization is based on results from the pivotal 2 Phase III ARANOTE trial, which showed that darolutamide plus ADT reduced the risk of radiological progression or death by 46% compared to placebo plus ADT (HR 0.54; 95% CI 0.41–0.71; P<0.0001) in patients with mCSPC. With this additional marketing authorization, darolutamide plus ADT is the first and only ARi indicated in Canada for the treatment of adult patients with mCSPC, either with or without docetaxel. In addition, darolutamide is approved for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease. "This latest authorization reaffirms NUBEQA's role as a therapy for men with prostate cancer," said Shurjeel Choudhri, Senior Vice President and Head of Medical and Scientific Affairs for Bayer Canada. "We extend our thanks to the scientists, doctors, patients, and their families for their contributions that allowed us to offer this new treatment option for metastatic castration-sensitive prostate cancer." "Clinical data from the ARANOTE trial showed that darolutamide is both efficacious and well tolerated as a combination therapy with androgen-deprivation therapy," said Fred Saad, M.D., Professor and Chairman of Surgery and Director of Genitourinary Oncology at the University of Montreal Hospital Center (CHUM), and Principal Investigator of the ARANOTE trial. "Today's approval further expands options for how physicians can use Nubeqa in the treatment of mCSPC, giving them greater flexibility in choosing treatment plans for their patients." In Canada, prostate cancer is the most commonly diagnosed cancer among men, with an incidence rate of 119.7 cases per 100,000 men annually. 3 Among those who are diagnosed, there is a portion of patients who will present with metastatic castration-sensitive prostate cancer (mCSPC), which may occur either de novo (newly diagnosed with metastatic disease) or as metachronous (recurrent disease following treatment for localized prostate cancer). In Canada, approximately 8.6% of all new prostate cancer cases are diagnosed as de novo mCSPC. 4 Prognosis varies by disease stage, and while overall survival for prostate cancer is high, the 5-year net survival rate for patients with stage IV metastatic prostate cancer is approximately 41%, highlighting the need for optimized treatment strategies in this population. ² "Prostate cancer continues to have a significant impact on men and their families in Canada, with incidence and mortality rates that remain unacceptably high," said Dr. Stuart Edmonds, Executive Vice President for Mission, Research and Advocacy at the Canadian Cancer Society. "Bringing more treatments to patients faster offers new hope, greater choice, and the potential for improved outcomes." Darolutamide is developed jointly by Bayer and Orion Corporation, a globally operating Finnish pharmaceutical company. About the ARANOTE Trial The ARANOTE trial is a randomized, double-blind, placebo-controlled Phase III study designed to assess the efficacy and safety of darolutamide plus ADT in patients with mCSPC. 669 patients were randomized 2:1 to receive 600 mg of darolutamide twice daily or matching placebo in addition to ADT. The primary endpoint of this study is rPFS (radiographic progression-free survival), measured as time from randomization to date of first documented radiological progressive disease or death due to any cause, whichever occurs first. Secondary endpoints include overall survival (time to death from any cause), time to metastatic castration-resistant prostate cancer, time to initiation of subsequent systemic anti-cancer therapy, time to prostate-specific antigen (PSA) progression, PSA undetectable rates, time to pain progression, and safety assessments. Results from the Phase III ARANOTE trial were presented at ESMO 2024 and published in The Journal of Clinical Oncology. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, "Health for all, Hunger for none," the company's products and services are designed to help people, and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to Journal of Clinical Oncology: Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial Canadian Cancer Statistics Advisory Committee. Canadian Cancer Statistics 2023. Toronto, Ontario: Canadian Cancer Society; 2023. Canadian Cancer Society. Survival statistics for prostate cancer. 2021; Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. ___________________ SOURCE Bayer Inc.
Cision Canada
7 hours ago
- Cision Canada
Health Canada Approves Roche's Columvi® (glofitamab) as the First Bispecific Antibody in Canada for Relapsed or Refractory Diffuse Large B-Cell Lymphoma after Initial Therapy Français
DLBCL is an aggressive cancer with a high risk of progression meaning urgent and effective treatments are needed for people who relapse or have refractory disease This Columvi regimen offers an off-the-shelf and fixed-duration treatment option for those ineligible for transplant Approval is based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk of death compared to Rituxan plus chemotherapy 1 MISSISSAUGA, ON, Aug. 21, 2025 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that Health Canada has granted market authorization for Columvi® (glofitamab for injection) in combination with gemcitabine and oxaliplatin (GemOx) indicated for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma not otherwise (DLBCL NOS) specified who are not candidates for autologous stem cell transplant (ASCT). 1 With the approval, this Columvi combination is the first bispecific antibody regimen available for people with DLBCL in Canada whose cancer has returned or for those who did not respond to initial treatment. Columvi first received conditional marketing authorization in Canada in March 2023 for treatment after two or more lines of systemic therapy. 1 The Health Canada approval is supported by data from the pivotal Phase III STARGLO study. This randomized, open-label study compared Columvi plus gemcitabine and oxaliplatin (GemOx) to MabThera®/Rituxan® (rituximab) plus GemOx in patients with relapsed or refractory (R/R) DLBCL ineligible for autologous stem cell transplant (ASCT). At the primary analysis, the STARGLO study met its primary endpoint of overall survival, where results showed a 41% reduction in the risk of death (hazard ratio [HR]=0.59, p=0.011) for patients treated with Columvi plus GemOx compared to those treated with MabThera / Rituxan and GemOx. At an updated analysis, 58.5% of patients in the Columvi + GemOx arm achieve a complete response, compared to 25.3% in the R-GemOx arm. 10 With two years of follow-up, Columvi plus GemOx sustained a clinically meaningful benefit in OS compared to R-GemOx. 7 Safety of the combination appeared consistent with the known safety profiles of the individual medicines. 1 Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL). 5 It was estimated that in 2024, 11,700 Canadians were diagnosed with NHL, with 30-40% of these accounting for DLBCL cases. 2,8 Approximately four out of ten DLBCL patients will relapse after first-line treatment and the majority of patients who require subsequent lines of therapy have poor outcomes. 6 "DLBCL is an aggressive and life-threatening form of lymphoma, leaving many patients in urgent need of additional treatment options," said Antonella Rizza, CEO, Lymphoma Canada. "The availability of novel therapies has the potential to address critical gaps in care and offer new possibilities for patients who face relapse or have limited options." Whilst second-line treatment advances have been made, challenges with the accessibility of existing medicines and the aggressive nature of DLBCL underscore the urgent need for immediately available treatment options that can control the disease and improve survival. 9 "Many patients with relapsed or refractory DLBCL in Canada are ineligible for potentially curative but intensive therapies, such as autologous stem cell transplantation or CAR T-cell therapy, due to advanced age, comorbidities, refractory disease, or geographic barriers. These patients currently face limited treatment options and poor outcomes with standard chemotherapy," said Robert Puckrin MD FRCPC, Arthur Child Comprehensive Cancer Centre & University of Calgary. "Glofitamab in combination with GemOx offers an off-the-shelf, fixed-duration approach with a novel T-cell engaging mechanism of action. With consistent safety data and survival benefits observed in clinical studies, Glofitamab-GemOx provides an important new option for patients with relapsed or refractory DLBCL." "The approval of Columvi marks an important milestone for patients with relapsed or refractory DLBCL in Canada," said Reem Sorial, Hematology Franchise Head, Roche Canada. "By introducing this new option, we aim to support patients and healthcare professionals in addressing the challenges of managing this aggressive lymphoma." Columvi is part of Roche's industry-leading CD20xCD3 bispecific antibody program. Roche Canada continues to be committed to advancing innovative therapies for individuals affected by lymphoma. In collaboration with provincial and territorial jurisdictions, we will work to facilitate timely access to this treatment through public and private drug plans. Our aim is to deliver tailored solutions that address the evolving needs of individuals with blood cancers and the healthcare systems that treat them. About the Health Canada Authorization The Health Canada authorization is based on results from the pivotal phase III STARGLO study, where Columvi in combination with GemOx demonstrated a statistically significant and clinically meaningful overall survival (OS) improvement versus MabThera®/Rituxan® (rituximab) and GemOx (R-GemOx) in people with R/R DLBCL. In the primary analysis (conducted after a median follow-up of 11.3 months), there was a 41% reduction in the risk of death in patients treated with Columvi plus GemOx versus R-GemOx (hazard ratio [HR]=0.59, 95% CI: 0.40-0.89, p=0.011). The Columvi combination also met its key secondary endpoints, with a 63% reduction in risk of disease worsening or death (progression-free survival, PFS) compared to R-GemOx (HR=0.37; 95% CI: 0.25–0.55, p<0.001). Follow-up analyses were conducted after all patients had completed therapy (median follow-up of 20.7 months), showing a 25.5 month median OS for people treated with the Columvi combination, nearly double what was seen for people treated with R-GemOx at 12.9 months (HR=0.62, 95% CI: 0.43-0.88). Additionally, more than twice as many patients experienced a complete response (58.5% versus 25.3% respectively, with a difference of 33.2% [95% CI: 20.9-45.5]). Safety of the combination was consistent with the known safety profiles of the individual medicines. 1 About Columvi® (glofitamab for injection) In 2023, Columvi was approved as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from follicular lymphoma (trFL), or primary mediastinal B-cell lymphoma (PMBCL), who have two or more lines of systemic therapy, and are ineligible to receive or cannot receive CAR-T cell therapy or have previously received CAR-T cell therapy. Columvi comes as a concentrate for solution for infusion, with each vial containing either 2.5 mg (in 2.5 mL) or 10 mg (in 10 mL) of Columvi. Each mL contains 1 mg of Columvi. 1 About Diffuse Large B-cell Lymphoma (DLBCL) Lymphoma is the name for a group of blood cancers that develop in the lymphatic system and occur in two main types: Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). 3,4 In particular, diffuse large B-cell lymphoma (DLBCL) is an aggressive (fast-growing) blood cancer and the most common form of NHL. 5 While it is generally responsive to treatment in the frontline, as many as 40% of people will relapse or have refractory disease, at which time salvage therapy options are limited and survival is short. 6 About Roche in Hematology Roche has been developing medicines for people with malignant and non-malignant blood diseases for more than 25 years; our experience and knowledge in this therapeutic area runs deep. Today, we are investing more than ever in our effort to bring innovative treatment options to patients across a wide range of haematologic diseases. About Roche Canada At Roche Canada, patients and science are at the heart of everything we do. Our passion for science and our commitment to relentlessly pursuing the impossible for patients have made us one of the world's leading pharmaceutical, in-vitro diagnostics, and diabetes care management companies. With our combined strength in diagnostics and pharmaceuticals, we're driving healthcare forward, while ensuring we deliver meaningful benefits for patients and sustainable healthcare systems. We are committed to creating a world where we all have more time with the people we love. And we're adding our expertise in new areas, such as artificial intelligence, real world data collection and analysis and collaborating with many different sectors and industries. Having the courage to reinvent ourselves and question the status quo is what patients and healthcare systems expect from Roche - and our commitment is as strong today as it was on the first day of our Canadian journey in 1931. Today, Roche Canada employs nearly 2,000 people at its offices in Mississauga, Ontario, in Laval, Quebec, and across the country from coast to coast to coast. For more information, please visit or follow Roche Canada on LinkedIn. Roche Group Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. In recognising our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceutical industry by the Dow Jones Sustainability Indices for the fifteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit All trademarks used or mentioned in this release are protected by law. References SOURCE Hoffmann-La Roche Limited (Roche Canada)
